<DOC>
	<DOCNO>NCT00379808</DOCNO>
	<brief_summary>The purpose study determine whether particular substance involve inflammation , call leukotrienes , involve cause heart disease occur progress .</brief_summary>
	<brief_title>Study Arachidonate 5-Lipoxygenase Enzyme Affecting Risk Coronary Heart Disease</brief_title>
	<detailed_description>The focus study well understand adult develop heart disease others . There many know factor play role cause heart disease , diet lifestyle . Also , know inflammation , process body cause painful joint arthritis swell site injury , also contribute heart disease . In particular , address whether leukotrienes , component inflammation , involve promote heart disease . We study give subject high risk heart disease drug call montelukast cause leukotrienes reduce effect body . In addition comparison , give subject placebo amount time . These subject crossed-over receive either montelukast placebo depend treatment receive first . We compare subject use blood test see subject take montelukast show sign le inflammation cause early heart disease compare subject .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Current hypertension ( blood pressure &gt; 140/90 mmHg ) current use antihypertensive medication AND Current use lipidlowering medication Current use montelukast Poorly control hypertension , systolic blood pressure great 160 diastolic blood pressure great 100 Use steroid drug , nonsteroidal antiinflammatory drug antiinflammatory medication two week prior enrollment . ( low dose aspirin ( &lt; 325 mg ) OK , indication must cardiovascular ) Current recreational drug use Other cardiovascular disease previous cardiovascular event . These include : history angina pectoris history heart failure presence cardiac pacemaker history myocardial infarction previous revascularization procedure history cerebrovascular disease include stroke transient ischemic attack Pregnancy lactation Diabetes mellitus Lactose intolerance Contraindications montelukast therapy Alcoholism Known hepatic disease Existing chronic obstructive pulmonary disease , asthma , allergic rhinitis Active chronic immune , infectious , neoplastic inflammatory disease require therapy ( active Hepatitis B , Hepatitis C , human immunodeficiency virus ( HIV ) ) Immunosuppressant therapy know immunosuppression due disease high density lipoprotein ( HDL ) &lt; 40 mg/dL ( although would risk factor heart disease , preliminary data indicates montelukast may lower HDL level , exclude patient abnormally low HDL study ) Other criterion investigator discretion deem make subject poor candidate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>coronary heart disease</keyword>
	<keyword>montelukast</keyword>
	<keyword>inflammation</keyword>
</DOC>